TSHA Share Price Performance
US$4.37
3.11 (246.83%)
61.3% undervalued intrinsic discount
US$11.29
Fair Value
Price US$4.37
AnalystConsensusTarget US$11.29
AnalystHighTarget US$17.24
AnalystLowTarget US$7.00
Fair ValueUS$11.29
Share Pricen/a
Taysha Gene Therapies, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
TSHA Community Narratives
AN
Fair Value US$11.29 61.3% undervalued intrinsic discount
TSHA: Recent Breakthrough Therapy Designation Will Accelerate Approval In Rett Syndrome
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value US$17.24 74.6% undervalued intrinsic discount
Breakthrough Therapy Designation Will Drive Long Term Upside For This Gene Therapy Leader
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$7 37.6% undervalued intrinsic discount
Clinical And Regulatory Risks Around Rett Gene Therapy May Eventually Reward Patience
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
TSHA: Recent Breakthrough Therapy Designation Will Accelerate Approval In Rett Syndrome
Key Takeaways Advancements in TSHA-102 trials and regulatory discussions could expedite approval and boost future revenue and investor confidence. Strategic alignment with regulatory and market priorities could enhance trial success, market adoption, and long-term revenue growth.Read more
327
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
US$11.29
61.3% undervalued intrinsic discount
Fair Value
Profit Margin
12.87%
Future PE
234.74x
Price in 2029
US$13.85
Clinical And Regulatory Risks Around Rett Gene Therapy May Eventually Reward Patience
Catalysts About Taysha Gene Therapies Taysha Gene Therapies develops gene therapies for Rett syndrome, focusing on its TSHA-102 program. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$7
37.6% undervalued intrinsic discount
Fair Value
Profit Margin
16.24%
Future PE
190.22x
Price in 2029
US$8.6
Breakthrough Therapy Designation Will Drive Long Term Upside For This Gene Therapy Leader
Catalysts About Taysha Gene Therapies Taysha Gene Therapies is a clinical stage biotechnology company developing AAV based gene therapies for monogenic central nervous system disorders, with TSHA-102 for Rett syndrome as its lead program. What are the underlying business or industry changes driving this perspective?Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$17.24
74.6% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
289.15x
Price in 2028
US$21.18
Trending Discussion
Recently Updated Narratives
AN
TSHA: Rett Gene Therapy Trials And FDA Alignment Will Drive Future Upside
Fair Value: US$11.29 61.3% undervalued intrinsic discount
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Clinical And Regulatory Risks Around Rett Gene Therapy May Eventually Reward Patience
Fair Value: US$7 37.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Breakthrough Therapy Designation Will Drive Long Term Upside For This Gene Therapy Leader
Fair Value: US$17.24 74.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Taysha Gene Therapies, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.38
- 100.00%
- -1,115.27%
- 20.3%
About TSHA
- Founded
- 2019
- Employees
- 99
- CEO
- WebsiteView website
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
